Amanda J. Stolarz
Assistant Professor
Faculty Researcher
Pharmaceutical Science, College of Pharmacy
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Amanda J. Stolarz's research focuses on understanding and mitigating drug-induced lymphatic dysfunction and lymphedema. She investigates the mechanisms by which certain chemotherapies, such as doxorubicin, disrupt lymphatic vessel function, leading to fluid accumulation and swelling. Her work utilizes animal models, specifically rats, to evaluate the efficacy of potential therapeutic interventions. A significant area of her investigation involves the role of ryanodine receptors as therapeutic targets to prevent or reverse doxorubicin-induced lymphatic damage. This research is supported by a $368,387 grant from the NIH/National Cancer Institute, with Stolarz serving as the Principal Investigator.
Beyond her work on drug-induced lymphedema, Stolarz also explores broader aspects of vascular health and cellular mechanisms. Her publications address the role of PCSK9 in endothelial cell efferocytosis and vascular aging, as well as the potential of endothelial cells to function as macrophage-like gatekeepers. She has also investigated liposome formulations for tumor-targeted drug delivery in conjunction with radiation therapy. Stolarz leads a research group at the University of Arkansas for Medical Sciences, where she collaborates with several colleagues, including Soumiya Pal, Nancy J. Rusch, Ashim K. Bagchi, and Shengyu Mu, with whom she has co-authored multiple publications.
Metrics
- h-index: 10
- Publications: 29
- Citations: 293
Selected Publications
-
Abstract LB219: Proteomic signatures of doxorubicin-induced lymphatic dysfunction in tumor-bearing rats (2026)
-
Smooth muscle excitability (2025)
-
Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema (2025)
-
Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats (2024)
-
Proteomics Approach to Identify Anthracycline-induced Cardiotoxicity Mechanisms in Human Cardiac Fibroblasts (2024)
-
JoVE Video Dataset (2024)
-
Real-Time Evaluation of Absolute, Cytosolic, Free Ca<sup>2+</sup> and Corresponding Contractility in Isolated, Pressurized Lymph Vessels (2024)
-
PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging (2023)
-
Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy (2022)
-
Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy (2022)
-
Opinion: Endothelial Cells - Macrophage-Like Gatekeepers? (2022)
-
Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels (2022)
-
Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies (2022)
-
Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation (2021)
-
Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy (2021)
Federal Grants 1 $364,698 total
Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Doxorubicin suppression of lymphatic function and therapeutic reversal NIH Co-Investigator
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
Collaboration Network
Top Collaborators
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
- Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema
- Real-Time Evaluation of Absolute, Cytosolic, Free Ca<sup>2+</sup> and Corresponding Contractility in Isolated, Pressurized Lymph Vessels
- Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels
Showing 5 of 7 shared publications
- PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
- Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
- Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
- Real-Time Evaluation of Absolute, Cytosolic, Free Ca<sup>2+</sup> and Corresponding Contractility in Isolated, Pressurized Lymph Vessels
- JoVE Video Dataset
- Proteomics Approach to Identify Anthracycline-induced Cardiotoxicity Mechanisms in Human Cardiac Fibroblasts
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
- Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy
- Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
- Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy
- Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
- PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
- Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
- PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
- Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
Similar Researchers
Based on overlapping research topics